Hostname: page-component-5db58dd55d-pjp64 Total loading time: 0 Render date: 2026-05-28T09:33:11.271Z Has data issue: false hasContentIssue false
  • English
  • Français

Basic science: (November 2007)

Published online by Cambridge University Press:  01 February 2008

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Information

Type
Journals Watch
Information
Breast Cancer Online , Volume 11 , Issue 2 , February 2008 , e5
Copyright
Copyright © Cambridge University Press 2008

References

1.Alexe, G, Dalgin, GS, Scanfeld, D, Tamayo, P, Mesirov, JP, DeLisi, C, Harris, L, Barnard, N, Martel, M, Levine, AJ, Ganesan, S, Bhanot, G. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res 2007; 67: 10669–10676.CrossRefGoogle ScholarPubMed
2.Assender, JW, Gee, JMW, Lewis, I, Ellis, IO, Robertson, JFR, Nicholson, RI. Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer. J Clin Pathol 2007; 60: 1216–1221.CrossRefGoogle ScholarPubMed
3.Braunstein, S, Karpisheva, K, Pola, C, Goldberg, J, Hochman, T, Yee, H, Cangiarella, J, Arju, R, Formenti, SC, Schneider, RJ. A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol Cell 2007; 28: 501–512.CrossRefGoogle ScholarPubMed
4.Chlebowski, RT, Anderson, GL, Lane, DS, Aragaki, AK, Rohan, T, Yasmeen, S, Sarto, G, Rosenberg, CA, Hubbell, FA. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst 2007; 99: 1695–1705.CrossRefGoogle ScholarPubMed
5.Cicek, M, Iwaniec, UT, Goblirsch, MJ, Vrabel, A, Ruan, M, Clohisy, DR, Turner, RR, Oursler, MJ. 2-methoxyestradiol suppresses osteolytic breast cancer tumor progression in vivo. Cancer Res 2007; 67: 10106–10111.CrossRefGoogle ScholarPubMed
6.Curtis, CD, Likhite, VS, McLeod, IX, Yates, JR, Nardulli, AM. Interaction of the tumor metastasis suppressor nonmetastatic protein 23 homologue h1 and estrogen receptor α alters estrogen-responsive gene expression. Cancer Res 2007; 67: 10600–10607.CrossRefGoogle ScholarPubMed
7.Datta, S, Hoenerhoff, MJ, Bommi, P, Sainger, R, Guo, WP, Dimri, M, Band, H, Band, V, Green, JE, Dimri, GP. Bmi-1 cooperates with H-ras to transform human mammary epithelial cells via Dysregulation of multiple growth-regulatory pathways. Cancer Res 2007; 67: 10286–10295.CrossRefGoogle ScholarPubMed
8.Decock, J, Ji-Rong, L, Laxton, RC, Shu, XO, Hodgkinson, C, Hendrickx, W, Pearce, EG, Gao, YT, Pereira, AC, Paridaens, R, Zheng, W, Ye, S. Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis. Cancer Res 2007; 67: 10214–10221.CrossRefGoogle ScholarPubMed
9.Dowling, RJO, Zakikhani, M, Fantus, IG, Pollak, M, Sonenberg, N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67: 10804–10812.CrossRefGoogle ScholarPubMed
10.Easton, DF, Deffenbaugh, AM, Pruss, D, Frye, C, Wenstrup, RJ, Allen-Brady, K, Tavtigian, SV, Monteiro, ANA, Iversen, ES, Couch, FJ, Goldgar, DE. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 2007; 81: 873–883.CrossRefGoogle ScholarPubMed
11.Eilon, T, Groner, B, Barash, I. Tumors caused by overexpression and forced activation of Stat5 in mammary epithelial cells of transgenic mice are parity-dependent and developed in aged, postestropausal females. Int J Cancer 2007; 121: 1892–1902.CrossRefGoogle ScholarPubMed
12.Einbond, LS, Sue, T, Wu, HA, Friedman, R, Wang, XM, Ramirez, A, Kronenberg, F, Weinstein, IB. The growth inhibitory effect of actein on human breast cancer cells is associated with activation of stress response pathways. Int J Cancer 2007; 121: 2073–2083.CrossRefGoogle ScholarPubMed
13.Finn, RS, Dering, J, Ginther, C, Wilson, CA, Glaspy, P, Tchekmedyian, N, Slamon, DJ. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007; 105: 319–326.CrossRefGoogle ScholarPubMed
14.Gill, JK, Maskarinec, G, Wilkens, LR, Pike, MC, Henderson, BE, Kolonel, LN. Nonsteroidal antiinflammatory drugs and breast cancer risk – the multiethnic cohort. Am J Epidemiol 2007; 166: 1150–1158.CrossRefGoogle ScholarPubMed
15.Ginestier, C, Adelaide, J, Goncalves, A, Repellini, L, Sircoulomb, F, Letessier, A, Finetti, P, Geneix, J, Charafe-Jauffret, E, Bertucci, F, Jacquemier, J, Viens, P, Birnbaum, D. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. Oncogene 2007; 26: 7163–7169.CrossRefGoogle ScholarPubMed
16.Harrell, JC, Dye, WW, Harvell, DME, Pinto, M, Jedlicka, P, Sartorius, CA, Horwitz, KB. Estrogen insensitivity in a model of estrogen receptor-positive breast cancer lymph node metastasis. Cancer Res 2007; 67: 10582–10591.CrossRefGoogle Scholar
17.Harris, L, Fritsche, H, Mennel, R, Norton, L, Ravdin, P, Taube, S, Somerfield, MR, Hayes, DF, Bast, RC. American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287–5312.CrossRefGoogle Scholar
18.Hosey, AM, Gorski, JJ, Murray, MM, Quinn, JE, Chung, WY, Stewart, GE, James, CR, Farragher, SM, Mulligan, JM, Scott, AN, Dervan, PA, Johnston, PG, Couch, FJ, Daly, PA, Kay, E, McCann, A, Mullan, PB, Harkin, DP. Molecular basis for estrogen receptor α deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst 2007; 99: 1683–1694.CrossRefGoogle ScholarPubMed
19.Ignatiadis, M, Xenidis, N, Perraki, M, Apostolaki, S, Politaki, E, Kafousi, M, Stathopoulos, EN, Stathopoulou, A, Lianidou, E, Chlouverakis, G, Sotiriou, C, Georgoulias, V, Mavroudis, D. Different prognostic value of cytokeratin-19 mRNA-positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol 2007; 25: 5194–5202.CrossRefGoogle ScholarPubMed
20.Mertens-Talcott, SU, Chintharlapalli, S, Li, MR, Safe, S. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G(2)-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res 2007; 67: 11001–11011.CrossRefGoogle Scholar
21.Meslin, F, Hamai, A, Gao, P, Jalil, A, Cahuzac, N, Chouaib, S, Mehrpour, M. Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death. Cancer Res 2007; 67: 10910–10919.CrossRefGoogle ScholarPubMed
22.Naughton, C, MacLeod, K, Kuske, B, Clarke, R, Cameron, DA, Langdon, SP. Progressive loss of estrogen receptor α cofactor recruitment in endocrine resistance. Mol Endocrinol 2007; 21: 2615–2626.CrossRefGoogle ScholarPubMed
23.Pujana, MA, Han, JDJ, Starita, LM, Stevens, KN, Tewari, M, Ahn, JS, Rennert, G, Moreno, V, Kirchhoff, T, Gold, B, Assmann, V, ElShamy, WM, Rual, JF, Levine, D, Rozek, LS, Gelman, RS, Gunsalus, KC, Greenberg, RA, Sobhian, B, Bertin, N, Venkatesan, K, Ayivi-Guedehoussou, N, Sole, X, Hernandez, P, Lazaro, C, Nathanson, KL, Weber, BL, Cusick, ME, Hill, DE, Offit, K, Livingston, DM, Gruber, SB, Parvin, JD, Vidal, M. Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet 2007; 39: 1338–1349.CrossRefGoogle ScholarPubMed
24.Roarty, K, Serra, R. Wnt5a is required for proper mammary gland development and TGF-β-mediated inhibition of ductal growth. Development 2007; 134: 3929–3939.CrossRefGoogle ScholarPubMed
25.Schroth, W, Antoniadou, L, Fritz, P, Schwab, M, Muerdter, T, Zanger, UM, Simon, W, Eichelbaum, M, Brauch, H. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007; 25: 5187–5193.CrossRefGoogle ScholarPubMed
26.Schunke, D, Span, P, Ronneburg, H, Dittmer, A, Vetter, M, Holzhausen, HJ, Kantelhardt, E, Krenkel, S, Mueller, V, Sweep, F, Thomssen, C, Dittmer, J. Cyclooxygenase-2 is a target gene of rho GDP dissociation inhibitor β in breast cancer cells. Cancer Res 2007; 67: 10694–10702.CrossRefGoogle ScholarPubMed
27.Umanskaya, K, Radke, S, Chander, H, Monardo, R, Xu, X, Pan, ZQ, O’Connell, MJ, Germain, D. Skp2B stimulates mammary gland development by inhibiting REA, the repressor of the estrogen receptor. Mol Cell Biol 2007; 27: 7615–7622.CrossRefGoogle ScholarPubMed
28.Wang, Z, Dahiya, S, Provencher, H, Muir, B, Carney, E, Coser, K, Shioda, T, Ma, XJ, Sgroi, DC. The prognostic biomarkers HOXB13, IL17BR, and CHDH are regulated by estrogen in breast cancer. Clin Cancer Res 2007; 13: 6327–6334.CrossRefGoogle ScholarPubMed
29.Wienke, D, Davies, GC, Johnson, DA, Sturge, J, Lambros, MBK, Savage, K, Elsheikh, SE, Green, AR, Ellis, IO, Robertson, D, Reis-Filho, JS, Isacke, CM. The collagen receptor endo180 (CD280) is expressed on basal-like breast tumor cells and promotes tumor growth in vivo. Cancer Res 2007; 67: 10230–10240.CrossRefGoogle ScholarPubMed
30.Yang, XR, Pfeiffer, RM, Garcia-Closas, M, Rimm, DL, Lissowska, J, Brinton, LA, Peplonska, B, Hewitt, SM, Cartun, RW, Mandich, D, Sasano, H, Evans, DB, Sutter, TR, Sherman, ME. Hormonal markers in breast cancer: Coexpression, relationship with pathologic characteristics, and risk factor associations in a population-based study. Cancer Res 2007; 67: 10608–10617.CrossRefGoogle ScholarPubMed